Diversifying your Cancer Immunotherapy Investments with B cell Activation Approaches - Family Office Networks

Sign Up For Our Newsletter

Novel scientific insights to unlock the full potential of B cell therapeutics

Diversifying your Cancer Immunotherapy Investments with B cell Activation Approaches

Background on Company

Novel scientific insights to unlock the full potential of B cell therapeutics
Range of treatment opportunities for cancer immunotherapy and B cell-driven rare diseases
Lead program, AT-1965, advancing toward IND and initiation of solid tumor clinical study in 2H2020
Positive pre-IND interaction with FDA; alignment on 2020 IND submission and clinical initiation for AT-1965
Collaborative team with leadership across all biotech disciplines; premier scientific advisors and leading entrepreneur backers
Financing underway to fund AT-1965 clinical initiation and development

What you will learn from this webinar

How a B cell activation approach differs from other cancer immunotherapy approaches
How clinical data drives value creation in cancer immunotherapy
How AT-1965 is poised to lead the next frontier in cancer immunotherapy
How investment in Akamara will diversify your cancer immunotherapy portfolio